Stock Financial Ratios

NLNK / NewLink Genetics Corp financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price7.10
Volume620,900.00
Market Cap ($M)297.51
Enterprise Value ($M)187.52
Book Value ($M)129.47
Book Value / Share4.43
Price / Book2.44
NCAV ($M)122.63
NCAV / Share4.49
Price / NCAV-9.70
Income Statement (mra) ($M)
Revenue35.77
EBITDA-90.76
Net Income-85.16
Balance Sheet (mrq) ($M)
Cash & Equivalents120.70
Cash / Share4.17
Assets139.71
Liabilities33.25
Quick Ratio4.43
Current Ratio4.43
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.66
Return on Assets (ROA)-0.51
Return on Equity (ROE)-0.66
Identifiers and Descriptors
CUSIP651511107
Central Index Key (CIK)1126234
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
651511957
651511907
Share Statistics
Weighted Average Number Of Shares Outstanding Basic28,979,327
Preferred Stock Shares Outstanding0
Common Shares Outstanding29,216,429
Weighted Average Number Of Diluted Shares Outstanding28,979,327
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Intangibles Per Share0.00
Cash And Equivalents Per Share4.13
Accumulated Depreciation And Depletion Per Share0.00
Assets Current Per Share4.59
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Cash Per Share4.17
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Equity Per Share3.64
Liabilities Current Per Share0.00
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Assets Per Share4.78
Liabilities Per Share1.15
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Nektar And Bristol-Myers Squibb's Deal Could Be An Opportunity For NewLink

2018-02-20 seekingalpha
Nektar and BMY's PIVOT-02 trial provided proof of concept for the synergistic action between PD-1 inhibition and T-Cell proliferation by Nektar’s NKTR-214 with tolerable safety profile. (86-0)

Stocks To Watch: Digging For Gems In The Shakeout

2018-02-10 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (1619-20)

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

2018-01-09 seekingalpha
Today we will discuss the hostile takeover bid from Novo Nordisk (NVO) for clinical-stage Belgian biotech company Ablynx (OTCPK:ABLYF). (411-6)

IDO Inhibitors Poised To Win: A Summary Of Their Safety, MoA, And Efficacy

2018-01-04 seekingalpha
I was prompted to write this summary of the IDO inhibitor field by a recent, excellent, review by G. Prendergast and A. Muller about the history of IDO1 inhibitors. I can only urge anyone who wants to obtain deeper knowledge on the topic to read this review. In the following, I am going to focus on the different mechanism of action between the most advanced IDO1 inhibitors currently in clinical trials and compare, wherever feasible, clinical trials of IDO inhibitors with each other and with anti-PD1/CTLA4 combinations. (35-0)

CUSIP: 651511107